Baricitinib

Based on the pathogenesis of eosinophilic cellulitis, treatment targeting Janus kinase 1 and 2 should be developed to treat this disease, according to a study.

A 4 mg dose of baricitinib was associated with significant improvement over placebo in a number of efficacy parameters in patients with moderate to severe atopic dermatitis, according to a study.

NEW ORLEANS — In this Healio exclusive video, Brett King, MD, PhD, discusses data indicating that down titration of baricitinib after 52 weeks may not be the optimal treatment strategy for patients with alopecia areata.

Baricitinib met the primary endpoint in one phase 3 study of patients with systemic lupus erythematosus, but failed to meet the same endpoint in a second trial aiming to repeat the results, according to data published in The Lancet.

NEW ORLEANS — In this Healio exclusive video, Brett King, MD, PhD, discusses results from the BRAVE-AA1 and BRAVE-AA2 phase 3 clinical trials of baricitinib for patients with alopecia areata.

In this Healio video exclusive, Laura Korb Ferris, MD, PhD, discusses the efficacy of baricitinib treatment in concurrent scalp hair, eyebrow and eyelash responses.

NEW ORLEANS — Patients who responded to baricitinib treatment for alopecia areata continued to maintain those results with long-term treatment, according to a speaker at the American Academy of Dermatology Annual Meeting.

Prolonged use of baricitinib increased the drug’s efficacy in the treatment of adults with severe alopecia areata, according to two phase 3 trials.

MIAMI BEACH, Fla. — The past year has seen explosive development in Janus kinase inhibitors for dermatologic conditions, and it is possible they could continue to have indications throughout the specialty, according to a speaker here.

PHILADELPHIA — Patients with rheumatoid arthritis frequently switched between JAK inhibitors in Australia, according to a presentation at ACR Convergence 2022.